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Abstract 22 
There is an on-going trend for developing more sustainable salmon feed in which 23 
traditionally applied marine feed ingredients are replaced with alternatives. Processed 24 
animal products (PAPs) have been re-authorized as novel high quality protein 25 
ingredients in 2013. These PAPs may harbor undesirable substances such as 26 
pharmaceuticals and metabolites which are not previously associated with salmon 27 
farming, but might cause a potential risk for feed and food safety. To control these 28 
contaminants, an analytical strategy based on a generic extraction followed by ultra-29 
high performance liquid chromatography coupled to high resolution mass spectrometry 30 
(UHPLC-HRMS) using quadrupole time-of-flight mass analyzer (QTOF MS) was 31 
applied for wide scope screening. Quality control samples, consisting of PAP 32 
commodities spiked at 0.02, 0.1 and 0.2 mg/kg with 150 analytes, were injected in every 33 
sample batch to verify the overall method performance. The methodology was applied 34 
to 19 commercially available PAP samples from six different types of matrices from the 35 
EU animal rendering industry. This strategy allows assessing possible emergent risk 36 
exposition of the salmon farming industry to 1005 undesirables, including 37 
pharmaceuticals, several dyes and relevant metabolites. 38 
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INTRODUCTION 46 
Estimated global production of farmed salmon (including Salmo salar, Oncorhynchus 47 
kisutch, O. tshawytscha) in 2010 was approximately 1.8 million metric tonnes with 48 
expected production of around 2.9 million metric tonnes in 2020 (Tacon et al., 2008). 49 
Furthermore, consumption of all species of farmed fish is expected to exceed that of 50 
feral fish (FAO, 2014). Traditional commercial feed for farmed salmon and rainbow 51 
trout are based on marine feed ingredients extracted from pelagic fish stocks. Concern 52 
of pressure on feral fish stocks and limited fish meal and fish oil availability to supply a 53 
rapidly growing aquaculture industry has led to the development of aquafeeds in which 54 
marine resources are replaced with alternative feed ingredients to develop more 55 
sustainable marine aquafeeds (Tacon et al., 2008; Torrisen et al., 2011; Waago et al., 56 
2013). On a global basis, processed animal products (PAP) from the rendering industry 57 
constitute one of the largest sources of high quality animal protein available for animal 58 
feed production (Toldra et al., 2012). The use of PAPs such as feather meal, poultry by-59 
product meal, pork meat and bone meal, and poultry and pork blood meal have been 60 
shown to be relevant nutritional replacements of fish meal for many cultured fish 61 
species including salmonids (Brandsen et al., 2001; Rosenlund et al., 2001; Yanik et al., 62 
2003; Rahnema et al., 2007; Wilson et al., 2007; Friesen et al., 2008; Poppi et al., 2011; 63 
Burr et al., 2012). However, following the peak outbreaks of transmissible spongiform 64 
encephalopathies (TSE) in the UK in the early 1990’s, the use of PAPs in all animal 65 
feed was banned in the European Union (EU) in 2001 (EC, 2001; EC, 2003a). 66 
Following a bovine spongiform encephalopathies (BSE) risk assessment by the 67 
European Food Safety Authorities (EFSA) (EFSA, 2011), the EU set out a working plan 68 
for the re-authorization of the use of non-ruminant PAPs in animal feed, initially for 69 
aquafeeds in 2013 (EC, 2013a). 70 
In EU, the use of veterinary drugs is regulated according to EU legislation. Permitted 71 
residue levels of pharmaceutical substances (EC, 2009a) and mandatory monitoring 72 
activity (EC, 1996) have been established for all food producing animals. These 73 
regulations affect the legal addition of pharmaceuticals to animal feed, including the 74 
prohibition of substances in feeds that have hormonal or thyreostatic action as well as β-75 
agonist (EC, 2003b). In addition, the supplementation of coccidiostats or histomonostats 76 
as feed additive causing unavoidable carry-over in non-target feed is regulated in the 77 
EU (EC, 2009b). In Norway, the use of pharmaceuticals in Atlantic salmon farming is 78 
under strict control and all sales of pharmaceuticals in animal farming have to be 79 
reported to the Norwegian Food Safety Authority. Open and reliable statistics on the 80 
consumption of therapeutic agents in aquaculture is only available from some nations. 81 
As an example, the registered use of pharmaceuticals in Norwegian aquaculture in 2014 82 
included the antimicrobials florfenicol and oxolinic acid, the anti-parasitic agents 83 
azametifos, cypermetrin, deltametrin, diflubenzuron, teflubenzuron, emamectin, 84 
praziquantel and hydrogen peroxide, as well as the anaesthetic agents benzocaine, 85 
metacaine and isoeugenol (available at http://www.fhi.no/artikler/?id=114175 ) (Grave 86 
et al., 2008). 87 
The use of PAPs in salmon feed can potentially introduce new chemical undesirables 88 
that have not been previously associated with farmed Atlantic salmon. Of special 89 
interest are pharmaceuticals such as antibacterials, which are used in all sectors of 90 
farming, including poultry and swine production (Toldra et al., 2012). Other 91 
pharmaceutical agents used in terrestrial farmed animals include antiparasitic agents 92 
such as coccidiostats, which are added to poultry feed to cope with protozoa as well as 93 
enhancing animal growth (Ruff, 1999; Chapman, 2014). It should be kept in mind that 94 
the number of pharmaceuticals used in terrestrial animals is more diverse than those 95 
used for fish, and that there are substantial differences in the prescribing patterns of 96 
veterinary agents between countries and regions (EMA, 2011). Earlier screening studies 97 
on feather meal from the USA (10 samples) and China (2 samples) for 59 98 
pharmaceuticals, showed the presence of six classes of antimicrobials including 99 
fluoroquinolones, tetracyclines, folic acid antagonists, and streptogramins (Love et al., 100 
2012). Two of the main antibacterials were enrofloxacin and ciprofloxacin, and studies 101 
in EU also showed the occurrence of these substances in poultry and pork PAPs 102 
(Berntssen et al., 2014). In addition to potentially direct adverse health effects of 103 
pharmaceutical residues in food and non-compliance with food legislation, concern has 104 
been raised for the development of resistant pathogenic microorganisms when exposed 105 
to low non-clinical residue levels (Reig et al., 2009; Blazquez et al., 2012; Gillings et 106 
al., 2013). 107 
The list of prohibited and allowed antibiotics in the EU includes many substances which 108 
may co-occur in samples of animal origin. This requires the use of comprehensive 109 
screening methods for detection of these substances (Bohn et al., 2013; Nácher-Mestre, 110 
et al., 2013; Masiá et al., 2014; Turnipseed et al., 2014; Boix et al., 2014). Therefore, 111 
generic sample treatment is advisable to cover as many compounds as possible during 112 
the experimental process. High resolution mass spectrometry (HRMS) allows the 113 
acquisition of full-spectrum accurate-mass data using analyzers such as quadrupole 114 
time-of-flight (QTOF). The coupling of liquid chromatography (LC) with QTOF MS is 115 
nowadays one of the most efficient analytical tools to face the investigation of large 116 
number of medium-high polar organic contaminants and residues in food-safety and 117 
related fields (Ibañez et al., 2012). The present study reports a wide-scope qualitative 118 
screening approach for 1005 permitted and prohibited pharmaceutical residues (also 119 
including metabolites) and dyes in commercially available EU produced PAPs with 120 
potential use in aquafeed. 121 
MATERIAL AND METHODS 122 
Reagents and chemicals. 150 reference standards were purchased from Acros Organics 123 
(Geel, Belgium), Aventis Pharma (Madrid, Spain), Bayer Hispania (Barcelona, Spain), 124 
Cerilliant (Round Rock, TX, USA), Fluka (Buchs, Switzerland), Dr. Ehrenstorfer 125 
(Augsburg, Germany), Fort Dodge Veterinaria (Gerona, Spain), National Measurement 126 
Institute (Pymble, Australia), Riedel-de Haën (Seelze, Germany), Sigma Aldrich (St 127 
Louis, MO, USA), Vetoquinol Industrial (Madrid, Spain), and Witega (Berlin, 128 
Germany). All reference materials had purities higher than 98% (w/w), except for 129 
marbofloxacin and pefloxacin, which had purities higher than 93%. 130 
HPLC-grade water was obtained from a MilliQ water purification system (Millipore 131 
Ltd., Bedford, MA, USA). HPLC-grade methanol, HPLC-supragradient acetonitrile and 132 
acetone for residue analysis were purchased from Scharlab (Barcelona, Spain). Formic 133 
acid (HCOOH, content > 98%), ammonium acetate (NH4Ac, reagent grade) and sodium 134 
hydroxide (NaOH, reagent grade) were supplied by Scharlab. Leucine enkephalin was 135 
purchased from Sigma Aldrich. 136 
 137 
Samples. Commercially available PAPs were studied in this work. A total of 19 138 
available non-ruminant PAPs from 6 different types of matrices were provided by the 139 
European Fat Processors and Renderers Association (EFPRA). The samples had been 140 
produced in different rendering factories. All PAPs were produced according to EU 141 
regulation for PAPs intended for use as feed ingredients (EC, 2001; EC, 2009c). All 142 
PAPs were “category 3 products” which are fit for human consumption at the point of 143 
slaughter as defined by EU-legislation (EC, 2009c). The PAPs obtained included six 144 
different matrices: poultry blood meal (n=4), poultry meal (n=4), feather meal (n=3), 145 
pork blood meal (n=3), pork meal (n=3) and pork greaves (n=2). Samples were stored at 146 
-20°C until analysis (within one week). The PAPs included are all produced in central 147 
Europe and are firmly considered to be used for future aquafeeds after the lift of the ban 148 
on these products in the EU food supply chain. 149 
 150 
Instrumentation. A Waters Acquity UHPLC system (Waters, Milford, MA, USA) was 151 
coupled to a quadrupole-orthogonal acceleration-TOF mass spectrometer (XEVO G2 152 
QTOF, Waters Micromass, Manchester, UK), with a Z-spray-ESI interface, operating in 153 
both positive and negative ionization modes. An Acquity UHPLC BEH C18 1.7 µm 154 
particle size analytical column 2.1×100 mm (Waters) at a flow rate of 300 µL/min was 155 
employed for chromatographic separation. Mobile phase consisted of water/methanol 156 
gradient both with 0.01% HCOOH and 0.1mM NH4Ac. The percentage of organic 157 
modifier (B) was changed linearly as follows: 0 min, 10 %; 14 min, 90 %; 16 min, 90 158 
%; 16.01 min, 10 %; 18 min, 10 %. The column temperature was set at 40 ºC. Hybrid 159 
TOF MS resolution was approximately 20,000 at full width half maximum (FWHM), at 160 
m/z 556. MS data were acquired in the m/z range of 50-1000. A capillary voltage of 0.7 161 
kV in positive mode and 2.5 kV in negative mode were used with a cone voltage of 20 162 
V. Collision gas was argon 99.995% (Praxair, Valencia, Spain). The interface 163 
temperature was set to 650 ºC and the source temperature at 130 ºC.  164 
For MSE experiments (also known as all-ion fragmentation or broadband collision-165 
induced dissociation by other manufacturers), two sequential acquisition functions were 166 
created: in the low energy function (LE), a collision energy of 4 eV is selected, 167 
obtaining a conventional full spectrum where intact (de)protonated molecules/adducts 168 
are commonly observed ; in the high energy function (HE), a linear collision energy 169 
ramp from 15 to 40 eV is applied in order to induce ion fragmentation. In this way, 170 
fragmentation information is obtained in advance for all compounds in a single run 171 
without the need for re-injecting the sample in MS/MS mode. Scan time of 0.4 s was 172 
selected. 173 
Calibrations were conducted daily from m/z 50 to 1000 with a 1:1 mixture of 0.05M 174 
NaOH:5% HCOOH diluted (1:25) with acetonitrile:water (80:20), at a flow rate of  20 175 
µL/min. For automated accurate mass measurement (i.e. real-time calibration), a 176 
solution of leucine enkephalin (10 mg/L) in acetonitrile:water (50:50) at 0.1% HCOOH 177 
was used as lock mass and pumped at 30 µL/min through the lock-spray needle. The 178 
(de)protonated molecule of leucine enkephalin at m/z 556.2771 in positive mode and 179 
m/z 554.2615 in negative mode was used for recalibrating the mass axis and ensuring a 180 
robust accurate mass measurement along time. MS data were acquired in centroid mode 181 
and processed by the ChromaLynx XS application manager (within MassLynx v 4.1; 182 
Waters Corporation). 183 
 184 
Recommended analytical procedure. A generic sample procedure has been expanded 185 
to PAPs following a screening strategy previously validated for aquaculture matrices 186 
(Nácher-Mestre et al., 2013) and feed samples (Boix et al., 2014). Briefly, PAPs were 187 
thawed at room temperature and 2.5 g of sample (dry weight) was accurately weighed 188 
(precision 0.01g) in centrifuge tubes (50 mL) and homogenized in a Vortex with 10 mL 189 
acetonitrile:water (80:20, v/v) 0.1% HCOOH. After shaking the samples for one hour, 190 
the tubes were placed in an ultrasonic bath during 15 minutes followed by 191 
centrifugation at 4500 rpm for 10 min. Then, an aliquot of 1 mL of supernatant extract 192 
was transferred to an eppendorf vial, diluted with 1 mL of HPLC-grade water and stored 193 
in a freezer (minimum 2 hours) to precipitate proteins. After that, the extract was again 194 
centrifuged at 12000 rpm for 10 min and supernatant was transferred to another vial. 195 
Finally, 20 µL of the extract (final composition acetronitrile:water (40:60, v/v) 0.05% 196 
HCOOH) was injected into the UHPLC-QTOF MS.  197 
 198 
Quality assurance. Sample batches consisted of 20-30 vials, including 4 standards 199 
(only for qualitative purposes) and quality control samples (QCs). The reliability of the 200 
qualitative screening was assessed by the analysis of three QCs per matrix at different 201 
concentration levels. To this aim, six different PAPs (each representing the matrices 202 
studied, see samples section) were spiked with 150 pharmaceutical agents (including 4 203 
dyes, see Sup. info for more details) at three different concentration levels (0.02, 0.1 and 204 
0.2 mg/kg), and analyzed together with their respective “blanks”. Additionally, two 205 
method blanks were analyzed to assure that no laboratory contamination was introduced 206 
in the procedure. This approach was carried out following the spirit of European 207 
guidelines (EC, 2002; EC, 2013b). 208 
 209 
RESULTS AND DISCUSSION 210 
UHPLC-QTOF MS screening. Satisfactory chromatographic peaks, i.e. at least 10 211 
data points per peak, for all 150 compounds were obtained. Formic acid (0.01 %) was 212 
added to both water and methanol mobile phase solvents, favoring the formation of the 213 
protonated molecule in positive ionization mode. The addition of ammonium acetate in 214 
the mobile phase allowed improving peak shapes (Gracia-Lor et al., 2010). In general, 215 
the best results in terms of sensitivity were obtained under positive ionization mode 216 
selecting the protonated molecule as the main diagnostic ion. 217 
With the previous chromatographic conditions, the screening was applied on the basis 218 
of a compound database that is being continuously updated (Nácher-Mestre et al., 2013; 219 
Boix et al., 2014). At this stage, new pharmaceuticals were included into our previous 220 
lists in order to investigate their possible presence in PAP matrices of interest for 221 
salmon aquafeed. Individual standard solutions were injected to study MS 222 
fragmentation of each target analyte, achieving a final list of 150 analytes, which were 223 
also used for quality control of the qualitative screening. The selected compounds were 224 
representative from different families with quite different chemical-physical 225 
characteristics and were used to test the applicability of the screening. Briefly, 75% of 226 
the 150 compounds used in QC analysis were detected in all matrices at 0.2 mg/kg and 227 
65% at 0.1 mg/kg, decreasing down to 30% at the lowest spiking level of 0.02 mg/kg. 228 
Many of the compounds that could not be detected in all spiked samples were however 229 
detected in some of them, sometimes even in 5 out of 6 samples. In those cases, we did 230 
not consider the screening as satisfactory at the concentration level tested, as the 231 
requirement was to have 100% of positive samples detected. This was mostly due to the 232 
high variability in matrix composition between the samples used for preparing QCs. 233 
In addition to these 150 compounds, up to 855 compounds were searched in the samples 234 
making a total target list of 1005 compounds. The compound database used can be 235 
found in supporting information, including Retention time (Rt) (when the reference 236 
standard was available) and the elemental composition used for characterization. With 237 
so high number of compounds, it might be possible that some of them co-elute (for 238 
example, sulfaquinoxaline and sulfathiazole at 6.51 min). Under this situation, UHPLC 239 
was valuable for choosing almost co-eluting fragment ions that would correspond to the 240 
same precursor avoiding spectrum interferences that would complicate the identification 241 
process. Not only the retention time but also the chromatographic peak shape were 242 
taken into account to match each fragment ion to the correct “precursor ion”. Anyway, 243 
as a hybrid QTOF was used, additional MS/MS experiments could be performed, if 244 
necessary, in analysis of real-world samples for confirmation of positives in case of 245 
doubt. For adequate retention time comparison, LC conditions used (LC column, mobile 246 
phase and gradient) should be the same than those used when creating the database.  247 
Detection and identification criteria. Figure 1 illustrates the criteria used in this work. 248 
The parameters considered for a satisfactory detection and identification were Rt, mass 249 
accuracy (i.e. mass errors), qi/Q ratios (Q: the most abundant ion –commonly the 250 
(de)protonated molecule; qi: fragment ion –or occasionally an adduct) and the isotopic 251 
distribution pattern (especially for Cl and Br) (Hernández et al., 2015). Requirements 252 
and interpretation of results were in agreement with Commission Decision 253 
2002/657/EC, which applies to the monitoring of certain substances and residues 254 
thereof in live animals and animal products (EC, 2002). In addition, SANCO guideline 255 
for pesticide residue analysis in food was of help in terms of mass accuracy 256 
requirements (EC, 2013b). The key parameters when testing the screening were 257 
detection and identification of the compound in the sample at the concentration levels 258 
tested. Neither recovery nor precision were calculated (contrarily to quantitative 259 
methods), which is in the line of the guidelines used nowadays in food safety or doping 260 
control analysis (EC, 2002; EC, 2013b; FDA, 2015; WADA 2010). Several situations 261 
were considered in the screening depending on the reference standard availability 262 
(Figure 1):  263 
1) Reference standard available: 264 
- Detection was considered satisfactory when the most abundant ion (Q), 265 
commonly the (de)protonated molecule, was found at the expected Rt (deviation 266 
accepted ± 2.5% in comparison with the reference standard) (EC, 2002) and 267 
mass error was below 5 ppm (named as “d1”) (EC, 2013b). Another likely 268 
situation for detection was to find two representative m/z ions (i.e. the most 269 
abundant ion (Q) and/or minor fragment/adduct ions (q)) for the target 270 
compound at the expected Rt, but with mass errors between 5-20 ppm (named as 271 
“d2”). The latter situation seemed to occur when the signal intensity was low 272 
(favored at low analyte concentrations). In that case, an additional effort is 273 
recommended to investigate more accurate-mass ions and/or repeat sample 274 
injection, if possible. 275 
- Identification was based on the presence of at least two representative m/z ions 276 
(Q, q) at the expected Rt (± 2.5%, in comparison with the reference standard) 277 
with mass errors below 5 ppm. Additionally, q/Q ratios should fit with those for 278 
reference standards within tolerance limits admitted which range from 20% to 279 
50 % depending on the q/Q ratio (<0.1:50%, 0.1-0.2:30%, 0.2-0.5:25% and, 280 
>0.5%:20%) (EC, 2002). Identification under these conditions was highly 281 
reliable and it was considered as the ideal situation.  282 
In both cases, the characteristic isotopic pattern (e.g. when ions as Cl or Br are 283 
present) should be observed.  284 
2) Reference standard not available:  285 
- Tentative identification could be made when an expected ion with mass error below 286 
5 ppm was observed, together with its characteristic isotopic pattern. Subsequently, 287 
the fragment ions (qi) (or characteristic isotopic ions) were evaluated. For this 288 
purpose, different possibilities are available, such as comparing experimental 289 
MS(/MS) spectra or the main fragment ions with those reported in the literature 290 
(massbank, METLIN public library), or justifying the accurate-mass fragments 291 
taking into account the structure of the molecule. So, tentative identification 292 
required the presence of one or more fragment ions (q) compatible with the 293 
chemical structure of the candidate (mass error < 5 ppm) and/or in agreement with 294 
previous data reported in literature. Retention time prediction may also help in this 295 
process (focusing research only on “predicted” peaks) (Bade et al., 2015). Although 296 
tentative identification was strongly supported by accurate-mass data obtained, the 297 
confirmation of the identity requires the injection of the reference standard.   298 
 299 
Screening of PAP samples. The HRMS screening developed allows research 300 
laboratories to apply a cost-effective strategy to extend their analytical scope to analytes 301 
which might potentially be present in the samples even without the need of having all 302 
reference standards (EC, 2013b). In this way, laboratories do not need to acquire all 303 
reference standards before analysis, with the subsequent problems of availability (e.g. 304 
metabolites and transformation products), costs and expiry dates. Accurate-mass full-305 
spectrum acquisition capabilities of the TOF analyzer made feasible the investigation of 306 
many undesirables in a single run injection. In absence of standards, the only 307 
information available for data processing was the elemental composition (i.e. accurate-308 
mass), but a tentative identification could be made if sufficient information was 309 
obtained from analyses (see Figure 1).  310 
With the objective to support the reliability of the screening procedure, figure 2 shows a 311 
sample matrix (poultry meal) fortified with the antibiotic enrofloxacin. The standard of 312 
this fluoroquinolone was previously injected, selecting two representative m/z ions, the 313 
protonated molecule (Q) and one fragment ion (q) for the reliable identification (Figure 314 
2-A). Figure 2-B shows the same m/z ions of a quality control sample at 0.1 mg/kg 315 
supporting the suitability of the method at this concentration level (mass deviations and 316 
q/Q were satisfactory). Finally, figure 2-C shows the identification of enrofloxacin in a 317 
PAP sample. The presence of two m/z ions, measured at the expected retention time, 318 
with acceptable mass deviations and appropriate q/Q ratios, allowed to identify this 319 
compound in that sample. 320 
After applying the described screening strategy to 19 PAP samples, pharmaceutic 321 
agents like monensin, flumequine, enrofloxacin, trimethoprim, tylosin A, 322 
acetaminophen, salicylic acid, oxyphenylbutazone, and the dye leucocrystal violet 323 
(metabolite of the crystal violet dye) were found (Table 1).  324 
Monensin is an antibiotic also allowed as a coccidiostat feed additive with an 325 
established maximum residue level (MRL is 1.25 mg/kg for feed materials) for 326 
unintended cross-contamination to non-target animal feed (EC, 2009b). The antibiotics 327 
flumequine, enrofloxacin, trimethoprim and tylosin A, are authorized pharmaceutical 328 
products in the EU with set MRLs in fish products (EC, 2009a); however in Norway, 329 
these pharmaceuticals have not been registered for aquaculture use for the last decade 330 
(Grave et al., 2008). The analgesics acetaminophen (paracetamol) is allowed to use for 331 
porcine, and salicylic acid is allowed to use for all food producing species except fin 332 
fish. Oxyphenylbutazone is a non-steroidal anti-inflammatory drug (NSAID) which is 333 
not listed as an authorized drug in the EC directive (EC, 2009b), and crystal violet is a 334 
potential carcinogenic pharmaceutical triphenylmethane dye, illegal for use in food-335 
producing animals in the EU (Serratosa et al., 2006). As opposed to the other 336 
pharmaceuticals identified in the study, crystal violet is not allowed to be used in the 337 
food production chain in the EU, and its potential source in PAPs is hence unclear. 338 
However, crystal violet can be unintendedly introduced as marker dye to identify treated 339 
farm animals. Outside the EU it is used as an antimicrobial agent to prevent the fungal 340 
growth in animal feeds (Mani and Bharagava, 2016). 341 
Figure 3 illustrates the identification of trimethoprim, flumequine and salicylic acid in 342 
different PAP samples analyzed. Figure 3-A corresponds to trimethoprim found in 343 
feather meal. Three representative m/z ions with mass deviations below 5 ppm were 344 
observed together with acceptable q/Q ratios. Figure 3-B corresponds to flumequine, 345 
also in feather meal, where two representative m/z ions were present with acceptable 346 
mass errors and q/Q deviations (<25%). However, in this sample the fragment with m/z 347 
174.036 was not clearly observed.  Finally, figure 3-C shows the identification of 348 
salicylic acid in pork blood meal with again two representative m/z ions. The fact that 349 
salicylic acid is a small molecule made that few fragments were available under the 350 
experimental conditions applied. Both salicylic acid and acetylsalicylic acid are allowed 351 
to be used in all food producing species except fin fish or use in animals from which 352 
milk or eggs are produced for human consumption (EC, 2009a). The presence of this 353 
analgesic might be related to the previous administration of acetylsalicylic acid in 354 
animals, a known pain reliever, anti-inflammatory and antipyretic drug, producing 355 
salicylic acid as a metabolite. Besides this, salicylic acid is also used as an agent against 356 
fungal diseases in the skin of animals. However, since salicylic acid is known to be 357 
found in several plants (Venema et al., 1996; Scotter et al., 2007), it could also be 358 
present in feed ingredients for livestock and subsequently in by-products from livestock 359 
animals. Furthermore, salicylic acid has been previously detected in man and animals 360 
not medicated by salicylic acid derived therapeutics (Paterson et al., 2008). 361 
Figure 4 illustrates two situations where the compounds detected in poultry blood meal 362 
could not be fully identified. Figure 4-A shows two m/z ions for leucocrystal violet but 363 
the m/z 239.1548 (q1), corresponding to the fragment C16H18N2, presented mass error 364 
higher than 5 ppm and further study of other fragment ions failed. In addition, q1/Q ratio 365 
was higher than 20% (tolerance permitted for q/Q>0.5). Therefore, the identification 366 
criteria were not met, and we considered this compound as detected but not identified 367 
(d2 following criteria from Figure 1). A similar situation occurred with tylosin A 368 
(Figure 4-B) for which three representative ions were found at the same Rt, in 369 
agreement with the standard. However, it was reported only as detected (d2) because all 370 
the ions presented high mass errors. This might be due to the high mass of this 371 
compound, very close to the higher end of the mass axis calibration range. Although it 372 
seemed that both compounds were present in the sample, they could not be identified in 373 
a reliable way; therefore, further analysis should be carried out for confirmation of their 374 
identity. 375 
The data processed also revealed the suspicious presence of ciprofloxacin and dyes such 376 
as crystal violet, malachite green and leucomalachite green in PAPs, but with such a 377 
low intensity that a second target analysis with a higher sensitivity technique (e.g. LC-378 
MS/MS with triple quadrupole) would be necessary. Thus, further work is required for 379 
those compounds identified (or tentatively identified) by this qualitative screening in 380 
order to confirm their presence and determine the concentration levels in the samples. 381 
This could be ideally made by LC-MS/MS using target quantitative methods developed 382 
for the compounds revealed by QTOF MS screening.  383 
In conclusion, the LC-HRMS screening methodology developed in this work has 384 
revealed the presence of some pharmaceutical agents and marker dyes in re-authorized 385 
PAPs that might be introduced in novel salmon feed. The qualitative validation was 386 
performed for 150 compounds, and it was satisfactory for a notable number of analytes. 387 
Most of compounds that could not be detected in 100% of the spiked samples were 388 
however detected in several of them (in some cases up to 5 out of 6 samples), 389 
illustrating that the screening was satisfactory in nearly all matrices tested. The lack of 390 
sensitivity seemed to be the main reason for the non-detections, a drawback that can be 391 
solved with the last-generation HRMS instruments that offer much better sensitivity that 392 
the QTOF MS used in the present work. 393 
Although the screening was tested for a limited number of compounds, it might be 394 
assumed to be applicable to the wide majority of the remaining compounds included in 395 
the database, as the contaminants used for validation covered a broad range of 396 
physicochemical properties. Obviously, the only way to ensure a completely reliable 397 
screening would be performing a full validation for all compounds, a task that seems 398 
extremely complicated when dealing with hundreds of analytes. Yet, in the present 399 
work, one can ensure the positive findings owing to the power of accurate-mass full 400 
spectrum acquisitions in HRMS, reaching reliable tentative identifications even when 401 
the standard is not available. Nevertheless, these tentative identified compounds should 402 
be confirmed by acquiring the reference standard in a subsequent step. A major 403 
advantage of this approach is that laboratories do not need to purchase hundreds of 404 
standards for compounds that in many cases will never be found in the samples. In fact, 405 
standards only need to be purchased in a subsequent step on the basis of the tentative 406 
identifications in the samples. However, this type of screening has the drawback that 407 
false negative results may occur for the compounds that have not been subjected to 408 
validation. The proposed strategy is of interest for food safety and public health control 409 
authorities as the presence of unintended background levels of illegal pharmaceutical 410 
dyes, unreported antibiotics, or unauthorized anti-inflammatory agents in salmon feed 411 
ingredients might give cause to legal actions. The approach presented in this paper can 412 
be considered as a useful risk assessment tool for feed industry in order to widen the 413 
knowledge on novel ingredients and also traditional ingredients under use. Also of 414 
interest is the fact that accurate-mass full-spectrum acquisition allows widening the 415 
search to other compounds not included in this work. This can be done at any time in 416 
the future by retrospective evaluation of data obtained without additional analysis. In 417 
the near future, routine monitoring and quantification of the compounds detected will be 418 
carried out due to the potential implications in food safety. 419 
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Figure captions. 617 
 618 
Figure 1. Scheme of detection and identification criteria for HRMS screening used in 619 
this work. 620 
Figure 2. nw-XICs for enrofloxacin in: (A) standard in solvent at 250 ng/mL; (B) 621 
quality control of poultry meal A at 0.1 mg/kg; (C) poultry meal C sample. In each case, 622 
chromatograms for the LE function (bottom) and HE (top) are shown to illustrate the 623 
presence of the protonated molecule (LE) and fragment ions (HE). ü Accurate mass 624 
deviations within tolerance limits (below 5 ppm). ü q/Q ratio tolerance accepted by 625 
Com. Decision 2002/657/EC. 626 
Figure 3. nw-XICs illustrating the identification of: (A) trimethoprim in feather meal; 627 
(B) flumequine in feather meal; (C) salicylic acid in pork blood meal. ü Accurate mass 628 
deviations within tolerance limits (below 5 ppm). ü qi/Q ratio tolerance accepted by 629 
Com. Decision 2002/657/EC. 630 
Figure 4. nw-XICs illustrating the detection of: (A) leucocrystal violet in poultry blood 631 
meal A; (B) tylosin A in poultry blood meal. ü/O Accurate mass deviations 632 
within/without tolerance limits. ü/O qi/Q ratio tolerance accepted/not permitted by 633 
Com. Decision 2002/657/EC. 634 
 635 
 636 
Table 1. Compounds detected and identified from the LC-HRMS screening. 637 
Pharmaceuticals  
& Dyes 
 
Poultry 
blood 
meal A 
Poultry 
blood 
meal B 
Poultry 
blood 
meal C 
Poultry 
blood 
meal D  
Poultry 
meal A 
Poultry 
meal B 
Poultry 
meal C 
Poultry 
meal D  
Feather 
meal A 
Feather 
meal B 
Feather 
meal C  
Pork 
blood 
meal 
A 
Pork 
blood 
meal 
B 
Pork 
blood 
meal 
C 
 
Pork 
meal 
A 
Pork 
meal 
B 
Pork 
meal 
C  
Pork 
greaves 
A 
Pork 
greaves 
B 
 Acetaminophen  - - - -  - d1 - d1  - - -  - - -  - - -  d1 -  
Enrofloxacin 
 
- - - -  - - ü -  - - -  - - -  - - -  - -  
Flumequine  - - - -  - - - -  ü - -  - - -  - - -  - -  
Leucocrystal violet 
 
d2 - - -  - - - -  - - -  - - -  - - -  - -  
Monensin 
 
- - - -  - - d1 -  - - -  - - -  - - -  - -  
Oxyphenylbutazone 
 
- d1 - -  - - - -  - - -  - - d1  - - -  - -  
Salicylic acid  ü ü ü ü  ü ü ü ü  ü ü ü  ü ü ü  d1 d1 d1  d1 d1  
Trimethoprim 
 
- - - -  - - - -  ü - -  - - -  - - -  - -  
Tylosin A   - - - d2  - - - -  - - -  - - -  - - -  - -  
d: detected (d1 and d2 are defined in Figure 1); ü: identified.  638 
 639 
 640 
 641 
 642 
 643 
 644 
 645 
Figure 1.  646 
Confirmation required with reference standard
Screening parameters
Accurate m/z ions - Retention time (Rt) - Mass errors - q/Q ratios - Isotope pattern (Cl, Br…)
Standard unavailableStandard available
Detection (d) Identification (ü)
• Two ions (Q, q)
• Rt agreement
• Mass error < 5 ppm
• qi/Q ratios
• Isotope pattern
• Expected ion (Q) present with mass error < 5 ppm
• Compatible isotope pattern (Cl, Br...)
• One or more fragment ions (q), 
- in agreement with data reported
- compatible with the chemical structure of the
candidate (mass error < 5 ppm)
Tentative identification
(d1)
• One ion (Q)
• Rt agreement
• Mass error < 5 ppm
• Isotope pattern
(d2)
• Two ions (Q, q)
• Rt agreement
• Mass error > 5 ppm
• Isotope pattern
 647 
Figure 2.  648 
MIX total 250ppb
Time
2.50 5.00 7.50
%
0
100
2.50 5.00 7.50
%
0
100
PAP119 Sm (Mn, 1x2) 2: TOF MS ES+ 
316.183 150PPM
1.80e6
Area
4.52
23168
PAP119 Sm (Mn, 1x2) 1: TOF MS ES+ 
360.172 150PPM
1.80e6
Area
4.52
151715
107 Poultry meal C
Time
2.50 5.00 7.50
%
0
100
2.50 5.00 7.50
%
0
100
PAP127 Sm (Mn, 2x3) 2: TOF MS ES+ 
316.183 150PPM
3.50e4
Area
4.53
840
PAP127 Sm (Mn, 2x3) 1: TOF MS ES+ 
360.172 150PPM
3.50e4
Area
4.52
6978
QC 105 Poultry meal A (0.1mg/kg)
Time
2.50 5.00 7.50
%
0
100
2.50 5.00 7.50
%
0
100
PAP108 Sm (Mn, 2x3) 2: TOF MS ES+ 
316.183 150PPM
3.50e4
Area
4.49
865
PAP108 Sm (Mn, 2x3) 1: TOF MS ES+ 
360.172 150PPM
3.50e4
Area
4.49
4547
Enrofloxacin
C19H22FN3O3
<	5.0	ppm	P
Q
q
Q
q
Q
q
C19H22FN3O3
1.0	ppm	P
C19H22FN3O3
1.9	ppm	P
C18H22FN3O
<	5.0	ppm	P
q/Q=0.15
C18H22FN3O
4.3	ppm	P
q/Q=0.19	(+27%) P
C18H22FN3O
4.1	ppm	P
q/Q=0.12	(-20%)P
A- Standard	at 250	ng/mL B- QC	Poultry meal A	at	0.1	mg/Kg C- Poultry meal C
c
 649 
Figure 3.  650 
109 Feather meal A
Time
5.00 10.00
%
0
100
5.00 10.00
%
0
100
5.00 10.00
%
0
100
PAP130 Sm (Mn, 5x3) 2: TOF MS ES+ 
261.099 150PPM
5.23e3
Area
3.74
1247
PAP130 Sm (Mn, 5x3) 2: TOF MS ES+ 
275.115 150PPM
4.83e3
Area
3.74
712
PAP130 Sm (Mn, 5x3) 1: TOF MS ES+ 
291.146 150PPM
5.62e4
Area
3.75
13517
109 Feather meal A
Time
6.00 8.00 10.00
%
0
100
6.00 8.00 10.00
%
0
100
6.00 8.00 10.00
%
0
100
PAP130 Sm (Mn, 2x3) 2: TOF MS ES+ 
174.036 150PPM
1.20e3
Area
PAP130 Sm (Mn, 2x3) 2: TOF MS ES+ 
202.03 150PPM
5.24e3
Area
8.36
588
PAP130 Sm (Mn, 2x3) 1: TOF MS ES+ 
262.088 150PPM
1.70e4
Area
8.36
2088
Trimethoprim
C14H18N4O3
<	5	ppm	P
C13H14N4O3
<	5	ppm	P
q1/Q=0.053	(-6%)	ü
C12H12N4O3
<	5	ppm	P
q2/Q=0.098	(-29%)	ü
Flumequine
C14H12NO3F
<	5	ppm	P
C11H4NO2F
<	5	ppm	P
q1/Q=0.28	(8%)	ü
114 Pork blood meal C
Time
4.00 6.00 8.00
%
0
100
4.00 6.00 8.00
%
0
100
4.00 6.00 8.00
%
0
100
PAP244 2: TOF MS ES- 
93.034 150PPM
1.88e3
4.78
3.95
4.71
5.95
4.86
6.05
8.518.296.78 8.68
PAP244 Sm (Mn, 2x3) 2: TOF MS ES- 
93.034 150PPM
1.03e3
Area
5.96
124
PAP244 Sm (Mn, 2x3) 1: TOF MS ES- 
137.024 150PPM
4.64e3
Area
5.96
703
Salicylic acid
C7H6O3
<	5	ppm	P
C6H6O
<	5	ppm	P
q1/Q=0.18	(3%)	ü
Q
q2
q1
A- Feather meal A B- Feather meal A C- Pork blood meal C
 651 
Figure 4.  652 
101 Poultry blood meal A
Time
8.00 10.00 12.00
%
0
100
8.00 10.00 12.00
%
0
100
8.00 10.00 12.00
%
0
100
PAP120 Sm (Mn, 5x3) 2: TOF MS ES+ 
359.236 100PPM
5.00e3
Area
PAP120 Sm (Mn, 5x3) 2: TOF MS ES+ 
239.155 100PPM
5.00e3
Area
11.36
241
PAP120 Sm (Mn, 5x3) 1: TOF MS ES+ 
374.26 100PPM
5.00e3
Area11.35
447
104 Poultry blood meal D
Time
9.00 10.00
%
0
100
9.00 10.00
%
0
100
9.00 10.00
%
0
100
PAP123 Sm (Mn, 2x3) 2: TOF MS ES+ 
174.113 150PPM
5.00e3
Area
9.44
261
PAP123 Sm (Mn, 2x3) 1: TOF MS ES+ 
948.553 150PPM
5.00e3
Area9.44
357
PAP123 Sm (Mn, 2x3) 1: TOF MS ES+ 
916.527 150PPM
5.00e3
Area
9.46
261
B- Poultry blood meal D
Tylosin A
C46H77NO17
>	5	ppm	O
C47H81NO18
>	5	ppm	O
q1/Q=1.36	(1%)	ü
C8H15NO3
>	5	ppm	O
q2/Q=1.0	(32%)	O
A- Poultry blood meal A
q2
q1
Q
Leucocrystal
violet
C25H31N3
<	5	ppm	P
C24H28N3
Missing peak
C16H18N2
>	5	ppm	O
q1/Q=0.53	(36%)O
